IPI-145: Phase II started

Infinity began the open-label, U.S. Phase II DYNAMO trial to evaluate 25 mg oral IPI-145 twice daily in 28-day cycles for up to 12 cycles in about 120 indolent NHL patients whose disease is refractory to radioimmunotherapy or a rituximab-containing chemotherapy regimen. IPI-145 is also in the Phase III DUO trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL). The product is also in Phase II testing in rheumatoid arthritis (RA) and Phase IIa testing in asthma. The compound has Orphan Drug designation in the U.S. and EU to treat CLL/SLL and in the U.S. to treat follicular lymphoma. ...